Evidence map›Paper›PMID 36522683›Full record

ArticleJournal of experimental & clinical cancer research : CR2022

IGF2BP2-induced circRUNX1 facilitates the growth and metastasis of esophageal squamous cell carcinoma through miR-449b-5p/FOXP3 axis.

Chang Wang, Mingxia Zhou, Peiyu Zhu, Chenxi Ju, Jinxiu Sheng, Dan Du, Junhu Wan, Huiqing Yin, Yurong Xing, Hongle Li and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Circular RNAs and Cancers.Advances in experimental medicine and biology · 2025
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Chang Wang *Department of Medical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Mingxia Zhou *Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Peiyu ZhuDepartment of Biomedical Informatics, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
Chenxi Ju *Department of Medical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Jinxiu ShengDepartment of Medical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Dan DuDepartment of Medical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Junhu WanDepartment of Medical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Huiqing YinDepartment of Medical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Yurong XingCenter of Health Examination, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Hongle LiDepartment of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450008, Henan, China. llhl73@163.com.
Jing HeDepartment of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. jinghe16@fudan.edu.cn.
Fucheng HeDepartment of Medical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. hefucheng@zzu.edu.cn.ORCID http://orcid.org/0000-0002-9024-1144
First Affiliated Hospital of Zhengzhou University · CNPeking University · CNZhengzhou University · CN

Funding

Key Medical Science and Technology Program of Henan Province SBGJ20210100National Natural Science Foundation of Chin 82203332National Natural Science Foundation of China 82173018National Natural Science Foundation of China 82272417Postdoctoral Research Foundation of China 2022TQ0302
6 · The paper itself

Abstract

backgroundEsophageal squamous cell carcinoma (ESCC) is one of the most common digestive malignancies with relatively high morbidity and mortality. Emerging evidence suggests circular RNAs (circRNAs) play critical roles in tumor cell malignancy. However, the biological function and clinical significance of many circRNAs in ESCC remain elusive.

methodsThe expression level and clinical implication of circRUNX1 in ESCC tissues were evaluated using qRT-PCR. In vitro and in vivo functional studies were conducted to investigate the underlying biological effects of circRUNX1 on ESCC cell growth and metastasis. Moreover, bioinformatics analysis, RNA sequencing (RNA-seq), RNA immunoprecipitation (RIP) assays, dual-luciferase reporter assays, and rescue experiments were performed to explore the relationships between circRUNX1, miR-449b-5p, Forkhead box protein P3 (FOXP3), and insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2).

resultsCircRUNX1 was found to be significantly up-regulated in ESCC tissues and associated with TNM stage and differentiation grade. Functionally, circRUNX1 promoted ESCC cell proliferation and metastasis in vitro and in vivo. CircRUNX1 enhanced FOXP3 expression by competitively sponging miR-449b-5p. Notably, both miR-449b-5p mimics and FOXP3 knockdown restored the effects of circRUNX1 overexpression on cell proliferation and metastasis. Furthermore, IGF2BP2 binding to circRUNX1 prevented its degradation.

conclusionsIGF2BP2 mediated circRUNX1 functions as an oncogenic factor to facilitate ESCC progression through the miR-449b-5p/FOXP3 axis, implying that circRUNX1 has the potential to be a promising diagnostic marker and therapeutic target for ESCC patients.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaMicroRNAsCell Line, TumorCell ProliferationForkhead Transcription FactorsGene Expression Regulation, NeoplasticHumansRNA-Binding ProteinsRNA, CircularForkhead Transcription FactorsFOXP3 protein, humanIGF2BP2 protein, humanMicroRNAsRNA-Binding ProteinsRNA, CircularBiomarkerCircRUNX1Esophageal squamous cell carcinoma (ESCC)FOXP3IGF2BP2

Identifiers

PMID36522683
PMCPMC9753396
OpenAlexW4311933216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.